3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide has been researched along with Schizophrenia in 2 studies
*Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basu, D; Johnson, RL; Kwiecien, JM; Mishra, RK; Tan, ML | 1 |
| Beyaert, MG; Daya, RP; Dyck, BA; Johnson, RL; Mishra, RK | 1 |
2 other study(ies) available for 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and Schizophrenia
| Article | Year |
|---|---|
Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antipsychotic Agents; Brain; Drug Evaluation, Preclinical; Humans; Male; Molecular Targeted Therapy; MSH Release-Inhibiting Hormone; Peptidomimetics; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia; Tissue Distribution | 2013 |
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Male; Motor Activity; Neostriatum; Nucleus Accumbens; Prefrontal Cortex; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Schizophrenia | 2013 |